GlobeNewswire·Nov 9, 2026, 9:21 AM ET

USARAD, a Nanox Company, Expands Collaboration with AZmed to Integrate FDA-Cleared X-ray AI into Its Teleradiology Workflows

Nanox Imaging's subsidiary USARAD is expanding its collaboration with AZmed to integrate AZmed's FDA-cleared X-ray AI suite into USARAD workflows via the Nanox Marketplace.
The integration covers AZmed's Rayvolve AI suite, which includes FDA-cleared tools for fractures & dislocations (AZtrauma), chest conditions like pneumothorax (AZchest), & pulmonary nodules (Rayvolve LN).
USARAD has utilized AZmed AI since 2023, initially for acute trauma & expanding to chest X-rays in 2026 to help radiologists prioritize & read studies more efficiently.
The AI solutions will be delivered through the Nanox Marketplace to enable automated study routing & DICOM transmission between AZmed & USARAD's OnePacs cloud PACS platform.
AZmed's Rayvolve AI suite was validated in the largest multicenter X-ray AI study to date, analyzing 258,373 X-rays from 100 medical centers across 26 countries.
USARAD CEO Elli Yuz & AZmed CEO Julien Vidal emphasized the value of end-to-end AI suites with clinical evidence for large-scale reading networks.
Both companies will showcase their collaboration at the RSNA 2026 conference at booths #1759 (Nanox) & #5509 (AZmed).
Nanox aims to lower barriers to care adoption by combining imaging hardware, AI, cloud infrastructure, & health IT solutions within its ecosystem.

Company: NANO-X IMAGING LTD
Keywords: Nasdaq:NNOX, NANO-X IMAGING LTD, USARAD, AZmed, Nanox, Elli Yuz, Julien Vidal, X-ray AI, Teleradiology